Market research
RCUS Arcus Biosciences Inc
NYSE USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 38.3333
- Dividend yield
- Not available
- Beta
- 0.81
Profile
Company facts
- Exchange
- NYSE
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US03969F1093
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- 38.3333
- Dividend yield
- Not available
- Beta
- 0.81
About
About Arcus Biosciences Inc
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the RCUS discussion.
5 years, 4 months ago
Arcus Biosciences, Inc is currently in a long term downtrend where the price is trading 1.4% below its 200 day moving average.
From a valuation standpoint, the stock is 98.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 23.0.
Arcus Biosciences, Inc's total revenue sank by 2.7% to $9M since the same quarter in the previous year.
Its net income has dropped by 212.4% to $-52M since the same quarter in the previous year.
Finally, its free cash flow grew by 99.5% to $-51K since the same quarter in the previous year.
Based on the above factors, Arcus Biosciences, Inc gets an overall score of 2/5.